Latest News - Movement Disorders

Monday, February 12, 2018 | Movement Disorders

Alkahest Receives Grant From the The Michael J. Fox Foundation for Parkinson's Research for Clinical Trial of GRF6019

On February 12, 2018, Alkahest, a privately-held clinical-stage company developing treatments for age-related diseases announced that they had received funding from the Michal J. Fox Foundation for Pa…

Read the full story

Friday, February 09, 2018 | Movement Disorders

National Institutes of Health Researchers Adapt Test for Early Diagnosis of Parkinson's Disease and Dementia with Lewy Bodies

Acta Neuropathologica Communications published a paper by researchers at the National Institutes of Health (NIH) (Groveman BR, Orrù CD, and Hughson AG, et al. Acta Neuropathol Comm. 2018;6:publ…

Read the full story

Thursday, February 08, 2018 | Movement Disorders

Two Surveys for Diagnosing Mild Cognitive Impairment in Parkinson's Disease

Approximately one-third of patients with Parkinson’s disease (PD) have dementia, leading to severe quality-of-life impairments in addition to those that are caused by the motor symptoms of PD. I…

Read the full story

Wednesday, February 07, 2018 | Clinical Trials, Movement Disorders, Phase 3/4 Trials

Phase 3 Trial of P2B001 for Early-Stage Parkinson's Disease Begins With First Patients Receiving First Dose

The drug P2B001(Pharma Two B) is a combination product of pramipexole 0.6mg and rasagiline 0.75 mg given together once daily. Rasagiline is a monoamine oxidase inhibitor used to treat Parkinson&r…

Read the full story

Monday, February 05, 2018 | Movement Disorders

Frozen Gait in Parkinson's Disease Is Influenced by Emotional Stimuli

In a study published in Movement Disorders, Lagravinese and colleagues have shown that gait initiation in patients with Parkinson’s disease (PD) is affected by the presence of an emotional stimu…

Read the full story

Tuesday, January 16, 2018 | Dementia & Cognitive Disorders, Movement Disorders

The Generational Technology Gap May Be Closing—Even in Patients with Dementia

Senior Helpers, a provider of in-home services for seniors who wish to remain in their homes despite age-related illnesses and mobility challenges including dementia, Alzheimer’s disease, and Pa…

Read the full story

Wednesday, January 10, 2018 | Movement Disorders

Parkinson’s Outcomes Project Enrolls 10,000th Patient and Releases Key Findings

The "Parkinson's Outcomes Project," launched in 2009 as a small pilot and funded by the Parkinson's Foundation, met a major milestone goal with the enrollment of its 10,000th pa…

Read the full story

Monday, January 08, 2018 | Movement Disorders, Sleep

Guidance for the Use of Opioids in the Treatment of Refractory Restless Leg Syndrome

On January 8, 2018, Mayo Clinic Proceedings published an article on appropriate use of opioids for treating refractory restless legs syndrome (RLS) by members of the Scientific and Medical Advisory Bo…

Read the full story

Wednesday, November 29, 2017 | Movement Disorders

Parkinson’s Advocates in Research Leadership Awards

November 29, 2017 -- The Parkinson's Foundation announced $60,000 in support of patient-scientist teams to develop innovations to engage patients in their care. These awards expand the Parkinson&#…

Read the full story

Thursday, September 14, 2017 | Movement Disorders, Research and Publications, Genentech

17 New Genes Linked to Parkinson’s Disease

A new study has discovered 17 novel genetic variants associated with Parkinson’s disease, several of which are considered targets for intervention. Published in Nature Genetics, the genome-wide …

Read the full story

Thursday, August 31, 2017 | FDA Approval/Clearance, Movement Disorders

Austedo Approved for Treatment of Tardive Dyskinesia

The FDA has approved Austedo (deutetrabenazine, Teva Pharmaceutical Industries Ltd.) tablets for the treatment of tardive dyskinesia in adults. The approval was based on results from two Phase 3 …

Read the full story

Tuesday, August 29, 2017 | Business of Medicine, Clinical Trials, Movement Disorders, Research and Publications

AstraZeneca and Takeda Strike $400 Million Development Deal for Investigational Parkinson’s Agent

AstraZeneca and Takeda Pharmaceutical Company Limited will jointly develop and commercialize an investigational alpha-synuclein antibody currently in development for the treatment of Parkinson’s…

Read the full story

Thursday, July 13, 2017 | Movement Disorders

Sage Bionetworks Launches DREAM Challenge to Identify Best Uses for Remote Sensing Devices

Sage Bionetworks has launched the Parkinson’s Disease Digital Biomarker DREAM Challenge, the first in a series of open, crowd-sourced analytical projects to help researchers identify ways to use…

Read the full story

Wednesday, July 12, 2017 | Movement Disorders, Research and Publications

Visual System Changes May Represent an Early Signal of Parkinson’s Disease

Changes in the intracranial visual system may be a signal of Parkinson’s disease (PD), according to new findings published in Radiology. Using MRI, researchers evaluated 21 patients with newly d…

Read the full story

Wednesday, June 14, 2017 | Movement Disorders, Phase 3/4 Trials, Research and Publications

Phase 3 Results Published for Investigational Levodopa-Induced Dyskinesia Treatment

Results from the Phase 3 EASE LID clinical trial, published online in JAMA Neurology, show that the investigational ADS-5102 (amantadine, Adamas Pharmaceuticals) reduces levodopa-induced dyskinesia (L…

Read the full story
Load More